Condition: Platinum-resistant Ovarian Cancer · Testicular Cancer · Endometrial Cancer · Sponsor: Context Therapeutics Inc.
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with platinum-refractory/resistant ovarian cancer (PRROC) and other advanced CLDN6-positive solid tumors (i.e., testicular and endometrial).
This description comes directly from the study's public registry record.
Context Clinical Development · 267-225-7416 · cntx-ctim76-101@contexttherapeutics.com
Always discuss trial participation with your own doctor first.
| University of Arkansas Winthrop P. Rockefeller Cancer Institute | Little Rock, Arkansas, United States | Recruiting |
| Precision NextGen Oncology & Research Center | Beverly Hills, California, United States | Withdrawn |
| SCRI at Denver Health | Denver, Colorado, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| John Theurer Cancer Center | Hackensack, New Jersey, United States | Terminated |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Recruiting |
| Duke Cancer Institute | Durham, North Carolina, United States | Recruiting |
| Gabrail Cancer Center | Canton, Ohio, United States | Withdrawn |
| Providence Cancer Institute of Oregon | Portland, Oregon, United States | Recruiting |
| Fox Chase Cancer Center | Philadelphia, Pennsylvania, United States | Withdrawn |
| Women & Infants Hospital of Rhode Island | Providence, Rhode Island, United States | Recruiting |
| Vanderbilt-Ingram Cancer Center | Nashville, Tennessee, United States | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06515613